噻吩并[2,3-c]吡啶-7(6h)-酮 | 28981-13-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 中文名称: 噻吩并[2,3-c]吡啶-7(6h)-酮
• 中文别名: 噻吩[2,3-C]并吡啶-7(6氢)-酮
• 英文名称: thieno[2,3-c]pyridin-7(6H)-one
• 英文别名: 6H-Thieno[2,3-c]pyridin-7-one
• CAS: 28981-13-7
• 化学式: C₇H₅NOS
• mdl: MFCD00122278
• 分子量: 151.189
• InChiKey: RIYCFWXOWRQFFK-UHFFFAOYSA-N

物化性质

• 熔点：
  195 °C
• 沸点：
  406.0±45.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  噻吩并[2,3-c]吡啶-7(6h)-酮 在 甲醇 、 sodium methylate 、 牛血清白蛋白 作用下， 以 乙腈 为溶剂， 反应 1.67h， 生成
  参考文献：
  名称：

  Determinants of Unnatural Nucleobase Stability and Polymerase Recognition

  摘要：

  Six new unnatural nucleobases have been synthesized and characterized in terms of stability and selectivity of self-pairing in duplex DNA and efficiency and fidelity of self-pairing during polymerase-mediated replication. Each nucleobase has a conserved ring structure but differs from the others in its specific pattern of substitution with oxygen and sulfur atoms. Heteroatom derivatization within the conserved scaffold is shown to have only moderate effects on unnatural self-pair synthesis by the polymerase; larger effects were observed on the thermal stability and polymerase-mediated extension of the self-pairs. The largest effects of heteroatom substitution were on the stability and synthesis of mispairs between the unnatural and natural bases. Certain heteroatom substitutions were found to have a general effect while others were found to have effects that were specific for a particular unnatural or natural base. The data are useful for designing stable and replicable third base pairs and for understanding the contributions of nucleobase shape, polarity, and polarizability to the stability and replication of DNA.

  DOI：

  10.1021/ja035398o
• 作为产物：
  描述：

  2-噻吩甲酸 在 草酰氯 、 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 cesium acetate 、 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 21.0h， 生成 噻吩并[2,3-c]吡啶-7(6h)-酮
  参考文献：
  名称：

  铑（III）催化的C–H活化/环化与乙烯基酯的乙炔当量

  摘要：

  研究了富电子烯烃在铑催化的CH活化/环化反应中的行为。乙酸乙烯酯以便利的乙炔当量出现，促进了16种3,4-未取代的异喹诺酮以及某些杂芳基稠合的吡啶酮的合成。讨论了烯醇醚相对于烯醇酯/烯酰胺的互补区域化学偏好。

  DOI：

  10.1021/ol502095z

文献信息

• 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS
  申请人：Bock Mark Gary

  公开号：US20140045872A1

  公开（公告）日：2014-02-13

  The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、A和n如本文所定义。还提供了式（I）化合物的氘代衍生物。
• Substituted sulfonic acid
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US06034093A1

  公开（公告）日：2000-03-07

  The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

  公式I的化合物表现出有用的药理活性，因此被纳入药物组合物中，并用于治疗患有某些医学疾病的患者。更具体地说，它们是凝血因子Xa活性的抑制剂。本发明涉及公式I的化合物、含有公式I化合物的组合物，以及它们的用途，用于治疗患有或受到可通过给予凝血因子Xa活性抑制剂而得到改善的生理状况的患者。
• [EN] BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] BENZOTHIOPHÈNE SULFONAMIDES ET AUTRES COMPOSÉS QUI INTERAGISSENT AVEC UNE PROTÉINE RÉGULATRICE DE LA GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2013173382A1

  公开（公告）日：2013-11-21

  The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及苯并噻吩磺胺类化合物以及与葡萄糖激酶调控蛋白相互作用的其他化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调控蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• Thienopyridine sulfonamides and their ophthalmological formulation
  申请人：Merck & Co., Inc.

  公开号：US04731368A1

  公开（公告）日：1988-03-15

  Thienopyridine sulfonamides are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure and disorders associated therewith such as glaucoma.

  噻吡啶磺酰胺是一种对碳酸酐酶具有抑制作用的药物，可用于治疗高眼压及相关疾病，如青光眼。
• Design and Synthesis of Piperazinylpyridine Derivatives as Novel 5-HT1A Agonists/5-HT3 Antagonists for the Treatment of Irritable Bowel Syndrome (IBS)
  作者：Akira Asagarasu、Teruaki Matsui、Hiroyuki Hayashi、Satoru Tamaoki、Yukinao Yamauchi、Michitaka Sato

  DOI：10.1248/cpb.57.34

  日期：——

  We have prepared a series of piperazinylpyridine derivatives for the treatment of irritable bowel syndrome (IBS). These compounds, which were designed by pharmacophore analysis, bind to both serotonin subtype 1A (5-HT1A) and subtype 3 (5-HT3) receptors. The nitrogen atom of the isoquinoline, a methoxy group and piperazine were essential to the pharmacophore for binding to these receptors. We also synthesized furo- and thienopyridine derivatives according to structure–activity relationship analyses. Compound 17c (TZB-20810) had high affinities to these receptors and exhibited 5-HT1A agonistic activity and 5-HT3 antagonistic activity concurrently, and is a promising drug for further development in the treatment of IBS.

  我们已准备了一系列哌嗪吡啶衍生物用于治疗肠易激综合征（IBS）。这些化合物通过药效团分析设计，能够同时与血清素亚型1A（5-HT1A）和亚型3（5-HT3）受体结合。异喹啉的氮原子、一个甲氧基和哌嗪是与这些受体结合的药效团的重要组成部分。我们还根据结构-活性关系分析合成了呋喃和噻吡啶衍生物。化合物17c（TZB-20810）对这些受体具有很高的亲和力，同时展现出5-HT1A激动剂活性和5-HT3拮抗剂活性，是治疗IBS方面具有进一步开发潜力的有前景药物。